查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
散瞳市场 - 全球和区域分析 - 分析和预测（2025-2035）
市场调查报告书
商品编码
1759272

散瞳市场 - 全球和区域分析 - 分析和预测（2025-2035）

Mydriasis Market - A Global and Regional Analysis: Focus on Country and Region - Analysis and Forecast, 2025-2035
出版日期: | 出版商: BIS Research | 英文 100 Pages | 商品交期: 1-5个工作天内

价格

散瞳是医学术语，指瞳孔扩张，即瞳孔变得异常大。

这种症状可能是在低光源环境下自然发生的（以便让更多光线进入眼睛），也可能是医学原因引起的。瞳孔扩张通常在眼科检查中被有意使用，以便更清晰地观察视网膜、视神经和眼内其他结构。它在诊断各种眼科疾病至关重要，包括青光眼、糖尿病视网膜病变和老龄化黄斑部病变(AMD)。

散瞳症可以透过使用托吡卡胺、苯肾上腺素或阿托品等散瞳药物来诱发，这些药物可以放鬆瞳孔周围的肌肉，使瞳孔扩张。虽然散瞳症通常是一种暂时性疾病，但神经系统疾病、眼外伤以及某些药物的作用也可能引起散瞳症。

散瞳市场的主要驱动力之一是对先进眼科诊断技术日益增长的需求。随着眼底摄影机、光同调断层扫瞄(OCT) 和视网膜影像处理系统等医学影像系统的不断改进，精确的瞳孔扩张对于最佳性能至关重要。

这些技术可以提供视网膜、视神经和其他重要眼内结构的高解析度影像，这些影像对于诊断青光眼、糖尿病视网膜病变和黄斑部病变等各种眼科疾病至关重要。在这种诊断中，散瞳对于获得清晰准确的影像至关重要，因此增加了对引起瞳孔扩张的散瞳药物的需求。随着这些诊断工具变得越来越普及和高效，对散瞳药物的需求持续增长，大大促进了散瞳药物市场的扩张。此外，慢性眼科疾病率的上升和全球人口老化进一步刺激了常规眼科检查中对瞳孔扩张的需求，使散瞳成为现代眼部保健的重要组成部分。

儘管散瞳剂市场正在成长，但仍有许多挑战阻碍其发展。其中最主要的挑战之一是散瞳剂的副作用和安全隐患。虽然这些药物可以有效地扩张瞳孔用于诊断，但它们可能导致眼部不适、眼压升高、畏光（对光敏感）和视力模糊。在某些情况下，它们还可能引起全身副作用，例如心率加快和高血压，尤其对于患有高血压或心血管疾病等潜在疾病的人。

此外，过度扩张的风险可能会使诊断过程复杂化，或在后续治疗中引起副作用。有些患者，尤其是老年人、糖尿病患者或青光眼患者，扩张过程可能有困难，可能需要额外的监测或调整。

此类安全隐患可能会限制散瞳剂的广泛使用，尤其是在脆弱的患者群体中，并减缓某些散瞳疗法的普及。这项挑战凸显了对更安全、更有效的替代方案的需求，这些方案既能达到诊断操作所需的瞳孔扩大程度，又能最大限度地减少副作用。

全球散瞳药市场竞争激烈，多家主要企业推动创新和市场成长。 Viatris Inc.、Opus Genetics、Eyenovia, Inc.、Rayner Surgical Group Limited、Omeros Corporation、爱尔康公司、诺华公司、辉瑞公司、Akorn, Inc. 和艾伯维公司等公司处于散瞳药技术进步和研发的前沿，以满足日益增长的眼科诊断需求。

这些公司在研发方面投入巨资，致力于提升散瞳药物治疗的疗效、安全性和病患体验。此外，策略合作伙伴关係、收购和产品系列扩展使这些公司保持了竞争力并提升了市场份额。随着眼底摄影机和光同调断层扫瞄(OCT) 等眼科成像技术的不断发展，这些公司将在塑造全球散瞳药物市场的未来方面发挥关键作用。

市场区隔

细分一：按地区

    • 北美洲
    • 欧洲
    • 亚太地区

全球散瞳市场正经历重大变革时期，其驱动力源自于重塑眼科诊断格局的几个关键因素。首先，眼底摄影机和光同调断层扫瞄(OCT) 等影像技术的快速发展，正在彻底改变眼科医师检查视网膜和视神经的方式。这些技术需要精确的瞳孔扩张才能捕捉高解析度、精细的影像，从而推动了对有效散瞳剂的需求。

其次，青光眼、糖尿病视网膜病变和白内障等慢性眼科疾病疾病的发生率不断上升，显着增加了定期进行瞳孔扩张诊断程序的需求。随着世界人口老化，尤其在已开发国家，对这些疾病的早期发现和管理的需求日益增加，以防止永久性视力丧失。

此外，新兴市场医疗保健服务的扩大也进一步推动了市场的成长，尤其是在亚太地区和拉丁美洲等地区，这些地区获取现代诊断工具的机会增加，导致接受需要散瞳眼科检查的患者数量增加。

最后，眼科领域对个人化医疗和精准诊断的日益重视，推动了散瞳治疗的创新。各公司正在开发更安全、起效更快的散瞳解决方案，以满足个别患者的需求，从而实现更有效率、更舒适的眼科检查。所有这些因素都推动着散瞳市场的持续转型，使其成为全球医疗保健领域中一个充满活力且快速变化的领域。

本报告研究了全球散瞳症市场，并提供了市场概述以及区域趋势和公司概况。

目录

执行摘要

第一章 全球散瞳市场：产业展望

  • 介绍
  • 市场趋势
  • 法律规范
  • 流行病学分析
  • 临床试验分析
  • 市场动态

2. 2023 年至 2035 年全球散瞳症市场（按地区）

  • 北美洲
  • 欧洲
  • 亚太地区

第三章全球散瞳药市场：竞争格局与公司概况

  • 关键策略和发展
    • 合併与收购
    • 协同活动
    • 业务扩展和资金筹措
    • 产品发布和核准
    • 其他活动
  • 公司简介
    • Viatris Inc.
    • Opus Genetics
    • Eyenovia, Inc.
    • Rayner Surgical Group Limited
    • Omeros Corporation
    • Alcon Inc.
    • Novartis AG
    • Pfizer Inc.
    • Akorn, Inc.
    • AbbVie Inc.

第四章调查方法

Product Code: BHL3067SA

Global Mydriasis Market, Analysis and Forecast: 2025-2035

Mydriasis is a medical term that refers to the dilation of the pupil, where the pupil becomes abnormally enlarged. This condition can occur naturally in response to low light conditions (to allow more light into the eye) or can be induced for medical reasons. Mydriasis is often used intentionally in ophthalmology during eye exams to provide a clearer view of the retina, optic nerve, and other structures inside the eye. It is essential for the diagnosis of various eye conditions, including glaucoma, diabetic retinopathy, and age-related macular degeneration (AMD).

Mydriasis can be induced using mydriatic agents, such as tropicamide, phenylephrine, or atropine, which relax the muscles around the pupil, causing it to dilate. While it is typically a temporary condition, mydriasis can also occur due to neurological disorders, eye trauma, or the effects of certain medications.

One of the key drivers of the mydriasis market is the growing demand for advanced ophthalmic diagnostic technologies. As medical imaging systems like fundus cameras, optical coherence tomography (OCT), and retinal imaging systems continue to improve, they require precise pupil dilation for optimal performance.

These technologies provide high-resolution images of the retina, optic nerve, and other critical structures inside the eye, which are essential for diagnosing a variety of eye diseases such as glaucoma, diabetic retinopathy, and macular degeneration. Mydriasis is crucial for obtaining clear, accurate images during these diagnostic procedures, which is driving the increased demand for mydriatic agents that induce pupil dilation. As these diagnostic tools become more widespread and more efficient, the need for mydriatic drugs continues to grow, significantly contributing to the expansion of the mydriasis market. Additionally, the rising prevalence of chronic eye conditions and the aging global population further fuel the demand for pupil dilation in routine eye exams, making mydriasis a critical component of modern ophthalmic care.

Despite the growth of the Mydriasis market, several challenges continue to hinder its progress. One of the primary challenges is the side effects and safety concerns associated with mydriatic agents. While these agents are effective in inducing pupil dilation for diagnostic purposes, they can cause ocular discomfort, increased intraocular pressure, photophobia (sensitivity to light), and blurred vision. In some cases, they may also cause systemic side effects, such as increased heart rate or high blood pressure, particularly in individuals with underlying health conditions like hypertension or cardiovascular diseases.

Additionally, there is a risk of over-dilation, which can complicate the diagnostic process or lead to adverse effects during subsequent treatment. Some patients, especially the elderly or those with diabetes or glaucoma, may experience difficulty with the dilation process, potentially requiring additional monitoring or adjustments.

These safety concerns limit the widespread use of mydriatic agents, especially in vulnerable patient populations, and may slow the adoption of certain types of mydriatic treatments. This challenge underscores the need for safer, more effective alternatives that can minimize side effects while still achieving the necessary level of pupil dilation for diagnostic procedures.

The global Mydriasis market is highly competitive, with several leading companies driving innovation and market growth. Companies such as Viatris Inc., Opus Genetics, Eyenovia, Inc., Rayner Surgical Group Limited, Omeros Corporation, Alcon Inc., Novartis AG, Pfizer Inc., Akorn, Inc., and AbbVie Inc. are at the forefront of advancing technologies and developing mydriatic agents to address the growing demand for ophthalmic diagnostics.

These companies are investing heavily in research and development (R&D), focusing on improving the efficacy, safety, and patient experience of mydriatic treatments. Furthermore, strategic partnerships, acquisitions, and expanding product portfolios are helping these companies maintain a competitive edge and expand their market presence. As ophthalmic imaging technologies like fundus cameras and optical coherence tomography (OCT) continue to evolve, these companies are poised to play a crucial role in shaping the future of mydriasis in the global market.

Market Segmentation:

Segmentation 1: by Region

    • North America
    • Europe
    • Asia-Pacific

The global Mydriasis market is undergoing significant transformation, fuelled by several key factors that are reshaping the landscape of ophthalmic diagnostics. First, the rapid advancements in imaging technologies such as fundus cameras and optical coherence tomography (OCT) are revolutionizing the way ophthalmologists examine the retina and optic nerve. These technologies require precise pupil dilation to capture high-resolution, detailed images, driving the demand for effective mydriatic agents.

Second, the rising prevalence of chronic eye conditions, including glaucoma, diabetic retinopathy, and cataracts, is significantly increasing the need for regular diagnostic procedures involving mydriasis. As the global population ages, particularly in developed countries, there is a greater need for early detection and management of these conditions to prevent permanent vision loss.

Moreover, the expansion of healthcare access in emerging markets is further accelerating market growth. As access to modern diagnostic tools improves, particularly in regions such as Asia-Pacific and Latin America, more patients are undergoing eye exams that require pupil dilation.

Finally, the growing emphasis on personalized medicine and precision diagnostics in ophthalmology is driving innovation in mydriasis treatments. Companies are developing safer, faster acting mydriatic agents tailored to individual patient needs, ensuring more efficient and comfortable eye exams. These factors are all contributing to the ongoing transformation of the mydriasis market, making it a dynamic and fast-evolving sector in the global healthcare landscape.

Table of Contents

Executive Summary

Scope and Definition

Market/Product Definition

Inclusion and Exclusion

Key Questions Answered

Analysis and Forecast Note

1. Global Mydriasis Market: Industry Outlook

  • 1.1 Introduction
  • 1.2 Market Trends
  • 1.3 Regulatory Framework
  • 1.4 Epidemiology Analysis
  • 1.5 Clinical Trial Analysis
  • 1.6 Market Dynamics
    • 1.6.1 Impact Analysis
    • 1.6.2 Market Drivers
    • 1.6.3 Market Challenges
    • 1.6.4 Market Opportunities

2. Global Mydriasis Market (Region), ($Billion), 2023-2035

  • 2.1 North America
    • 2.1.1 Key Findings
    • 2.1.2 Market Dynamics
    • 2.1.3 Market Sizing and Forecast
      • 2.1.3.1 North America Mydriasis Market, by Country
        • 2.1.3.1.1 U.S.
  • 2.2 Europe
    • 2.2.1 Key Findings
    • 2.2.2 Market Dynamics
    • 2.2.3 Market Sizing and Forecast
      • 2.2.3.1 Europe Mydriasis Market, by Country
        • 2.2.3.1.1 Germany
        • 2.2.3.1.2 U.K.
        • 2.2.3.1.3 France
        • 2.2.3.1.4 Italy
  • 2.3 Asia Pacific
    • 2.3.1 Key Findings
    • 2.3.2 Market Dynamics
    • 2.3.3 Market Sizing and Forecast
      • 2.3.3.1 Asia Pacific Mydriasis Market, by Country
        • 2.3.3.1.1 China
        • 2.3.3.1.2 Japan

3. Global Mydriasis Market: Competitive Landscape and Company Profiles

  • 3.1 Key Strategies and Development
    • 3.1.1 Mergers and Acquisitions
    • 3.1.2 Synergistic Activities
    • 3.1.3 Business Expansions and Funding
    • 3.1.4 Product Launches and Approvals
    • 3.1.5 Other Activities
  • 3.2 Company Profiles
    • 3.2.1 Viatris Inc.
      • 3.2.1.1 Overview
      • 3.2.1.2 Top Products / Product Portfolio
      • 3.2.1.3 Top Competitors
      • 3.2.1.4 Target Customers/End-Users
      • 3.2.1.5 Key Personnel
      • 3.2.1.6 Analyst View
    • 3.2.2 Opus Genetics
      • 3.2.2.1 Overview
      • 3.2.2.2 Top Products / Product Portfolio
      • 3.2.2.3 Top Competitors
      • 3.2.2.4 Target Customers/End-Users
      • 3.2.2.5 Key Personnel
      • 3.2.2.6 Analyst View
    • 3.2.3 Eyenovia, Inc.
      • 3.2.3.1 Overview
      • 3.2.3.2 Top Products / Product Portfolio
      • 3.2.3.3 Top Competitors
      • 3.2.3.4 Target Customers/End-Users
      • 3.2.3.5 Key Personnel
      • 3.2.3.6 Analyst View
    • 3.2.4 Rayner Surgical Group Limited
      • 3.2.4.1 Overview
      • 3.2.4.2 Top Products / Product Portfolio
      • 3.2.4.3 Top Competitors
      • 3.2.4.4 Target Customers/End-Users
      • 3.2.4.5 Key Personnel
      • 3.2.4.6 Analyst View
    • 3.2.5 Omeros Corporation
      • 3.2.5.1 Overview
      • 3.2.5.2 Top Products / Product Portfolio
      • 3.2.5.3 Top Competitors
      • 3.2.5.4 Target Customers/End-Users
      • 3.2.5.5 Key Personnel
      • 3.2.5.6 Analyst View
    • 3.2.6 Alcon Inc.
      • 3.2.6.1 Overview
      • 3.2.6.2 Top Products / Product Portfolio
      • 3.2.6.3 Top Competitors
      • 3.2.6.4 Target Customers/End-Users
      • 3.2.6.5 Key Personnel
      • 3.2.6.6 Analyst View
    • 3.2.7 Novartis AG
      • 3.2.7.1 Overview
      • 3.2.7.2 Top Products / Product Portfolio
      • 3.2.7.3 Top Competitors
      • 3.2.7.4 Target Customers/End-Users
      • 3.2.7.5 Key Personnel
      • 3.2.7.6 Analyst View
    • 3.2.8 Pfizer Inc.
      • 3.2.8.1 Overview
      • 3.2.8.2 Top Products / Product Portfolio
      • 3.2.8.3 Top Competitors
      • 3.2.8.4 Target Customers/End-Users
      • 3.2.8.5 Key Personnel
      • 3.2.8.6 Analyst View
    • 3.2.9 Akorn, Inc.
      • 3.2.9.1 Overview
      • 3.2.9.2 Top Products / Product Portfolio
      • 3.2.9.3 Top Competitors
      • 3.2.9.4 Target Customers/End-Users
      • 3.2.9.5 Key Personnel
      • 3.2.9.6 Analyst View
    • 3.2.10 AbbVie Inc.
      • 3.2.10.1 Overview
      • 3.2.10.2 Top Products / Product Portfolio
      • 3.2.10.3 Top Competitors
      • 3.2.10.4 Target Customers/End-Users
      • 3.2.10.5 Key Personnel
      • 3.2.10.6 Analyst View

4. Research Methodology

List of Figures

  • Figure: Global Mydriasis Market (by Region), $Billion, 2024 and 2035
  • Figure: Global Mydriasis Market Key Trends, Analysis

List of Tables

  • Table: Global Mydriasis Market Dynamics, Impact Analysis
  • Table: Global Mydriasis Market (by Region), $Billion, 2024-2035